

# Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma

NCT04056962

---

Status	RECRUITING
Phase	Phase 2
Sponsor	West China Hospital
Enrollment	50 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- Children with superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)

### Exclusion (1)

- Hypersensitivity to Tacrolimus Mucosal Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)

## Locations (1 total)

---

West China Hospital of Sichuan University, Chengdu, Sichuan, China